KaloBios Pharmaceuticals, Inc. (KBIO)

Oncology Corporate Profile

Stock Performance

2.1900
0.4600

HQ Location

260 East Grand Avenue
South San Francisco, CA 94080

Company Description

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

Website: http://www.kalobios.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
KB004anti-EphA3 monoclonal antibodyAcute Myelogenous Leukemia (AML)II
KB004anti-EphA3 monoclonal antibodyMyelodysplastic Syndrome (MDS)II
KB004anti-EphA3 monoclonal antibodyVarious cancer typesII

View additional information on product candidates here »

Source: http://www.kalobios.com

Recent News Headlines

8/18/2017 06:18 am

8/18/2017 06:18 am

8/18/2017 06:18 am

8/5/2017 06:19 pm

8/5/2017 06:19 pm

8/1/2017 06:32 am

7/12/2017 12:18 pm

7/12/2017 12:18 pm

7/11/2017 12:18 pm

7/11/2017 12:18 pm

6/27/2017 06:18 am

6/26/2017 12:19 am

5/31/2017 06:18 am

5/25/2017 06:18 am

5/2/2017 06:18 am

KaloBios to Participate in Inaugural U.S. Chagas Conference

3/30/2017 12:00 pm

[GlobeNewswire] - BRISBANE, Calif., March 30, 2017-- KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, ...

KaloBios Receives M&A Advisor 2017 Turnaround Award

3/27/2017 12:00 pm

[GlobeNewswire] - BRISBANE, Calif., March 27, 2017-- KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that it has ...

KaloBios to Present at 29th Annual ROTH Conference

3/9/2017 01:00 pm

[GlobeNewswire] - BRISBANE, Calif., March 09, 2017-- KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, ...

KaloBios to Present at Disruptive Growth & Healthcare Conference

2/13/2017 07:02 pm

[Accesswire] - BRISBANE, CA / ACCESSWIRE / February 13, 2017 / KaloBios Pharmaceuticals, Inc. (OTC PINK: KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, ...